TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00222040

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: 2-MHz, low intensity transcranial ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levovist
Description: D-Galactose and palmitic palmitique intravenous 4 g
Study: NCT03604549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol UF
Description: Up to 10cc of Lipiodol Ultra Fluid will be infused via intrauterine catheter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Up to 10cc of saline will be infused via intrauterine catheter
Study: NCT00600873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R(+) pramipexole dihydrochloride monohydrate
Description: 100 mg tid orally daily
Study: NCT03422224

Intervention type: DIAGNOSTIC_TEST
Intervention: Mixed lymphocyte reaction
Description: Assessment of alloreactive T cell repertoire

Intervention type: DIAGNOSTIC_TEST
Intervention: Mixed lymphocyte reaction
Description: Assessment of alloreactive T cell repertoire
Study: NCT01307943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program
Description: Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
Study: NCT00645944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or inactive substance (sugar pill)taken each night for all weeks of the study
Study: NCT01098539

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide
Description: albiglutide weekly subcutaneous injection + sitagliptin matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
Study: NCT02040961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView Double-Lumen Tube
Description: Tracheal intubation is performed using a ETView Double-Lumen Tube
Study: NCT01990807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin(IDA)
Description: 6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.
Study: NCT03121079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Description: patients in Interferon-alpha group will receive Interferon-alpha injection since the third month after transplantation for six months.
Study: NCT03501420

Intervention type: OTHER
Intervention: Interview
Description: A one hour survey interview will be completed by the rheumatologists which will contain open and closed questions to probe physician perception and behaviors in relation to pSS management and treatment

Intervention type: OTHER
Intervention: PSC questionnaire
Description: All subjects for whom the physician completes a PRF will be required to complete a PSC questionnaire independently of their physician, immediately after consultation.

Intervention type: OTHER
Intervention: PRFs
Description: PRFs will be completed by the physicians for seven of their consulting pSS subjects.
Study: NCT04024462

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-Operative Radiotherapy
Description: If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone Therapy
Description: For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Therapy
Description: For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
Study: NCT03449108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes LN-145
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes LN-145
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03554616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorfenapyr LLIN
Description: Dual active ingredient Long Lasting Insecticidal Net

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pyriproxyfen LLIN
Description: Dual active ingredient Long Lasting Insecticidal Net

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Piperonyl butoxide LLIN
Description: Combination insecticide and synergist Long Lasting Insecticidal Net
Study: NCT03019263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Nutritional counseling
Study: NCT04346654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
Study: NCT03923998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Three weekly concurrent chemotherapy with cisplatin 100 mg /m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
Study: NCT03554616

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard LLIN
Description: Standard Long Lasting Insecticidal Net with one insecticide
Study: NCT03923998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection and reconstruction
Description: Resection and reconstruction of mandibular/maxillary segment with prefabricated fibular graft
Study: NCT03428828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amygdala Neurofeedback
Description: Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietal Neurofeedback
Description: Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
Study: NCT02993666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bair Hugger
Description: forced air warming with Bair Hugger air warmer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bair Hugger
Description: forced air warming with Bair Hugger air warmer
Study: NCT01877057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturn
Study: NCT04493203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of Immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor.Its primary mechanism of action is thought to be vascular endothelial growth factor receptor 1-3, c-KIT and PDGFR inhibition, this, in turn, enables it to inhibit angiogenesis (the formation of new blood vessels by tumours)
Study: NCT00911157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium
Description: The dose of Fondaparinux will be determined based on a subject's body weight (\< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
Study: NCT02381197

Intervention type: DEVICE
Intervention: Congo Red Dot test
Description: The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
Study: NCT00911157

Intervention type: DRUG
Group type: OTHER
Intervention: unfractionated heparin (UFH)
Description: UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
Study: NCT04247841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Aid
Description: The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual discription stating the anticipated risk. For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scripted Risk Discussion
Description: The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scripted Risk Discussion
Description: The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
Study: NCT01671592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC Vaccine
Description: Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC Vaccine
Description: Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
Study: NCT02344498

Intervention type: DRUG
Intervention: Tenofovir disoproxil

Intervention type: DRUG
Intervention: Tenofovir disoproxil
Study: NCT01887600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
Study: NCT02137278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasoactive drug therapies
Description: Continue current vasoactive therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stop/reduce vasoactive drugs
Description: Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
Study: NCT01407341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: musculoskeletal complications management/prevention
Description: Receive beta tricalcium-phosphate bone graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone graft
Description: Receive beta tricalcium-phosphate bone graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03109769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal oral hygiene instructions
Study: NCT02980185

Intervention type: PROCEDURE
Intervention: Laparoscopic primary cytoreduction
Description: Primary cytoreduction for ovarian cancer performed through a completely minimally-invasive approach
Study: NCT05210140

Intervention type: DRUG
Intervention: Escitalopram
Description: Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is commercially known as ELORYQA®, Elicea®, Escital®,PRAMES® or Lata® in Serbia. The recommended dose for Major depressive disorder is 10mg/day. Based on the individual response, dose can be adjusted and the maximum dose is 20 mg/day; 5 mg/day dose is also available. Escitalopram is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia) and Panic disorder (with or without agoraphobia) by Medicines and Medical Devices Agency of Serbia.~In known CYP2C19 poor metabolizers, initial dose should be 5mg/day during first 2 weeks, and based on the individual response it can be increased up to maximum of 10 mg of escitalopram per day, according to the guidelines of Medicines and Medical Devices Agency of Serbia.

Intervention type: DRUG
Intervention: Escitalopram
Description: Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is commercially known as ELORYQA®, Elicea®, Escital®,PRAMES® or Lata® in Serbia. The recommended dose for Major depressive disorder is 10mg/day. Based on the individual response, dose can be adjusted and the maximum dose is 20 mg/day; 5 mg/day dose is also available. Escitalopram is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia) and Panic disorder (with or without agoraphobia) by Medicines and Medical Devices Agency of Serbia.~In known CYP2C19 poor metabolizers, initial dose should be 5mg/day during first 2 weeks, and based on the individual response it can be increased up to maximum of 10 mg of escitalopram per day, according to the guidelines of Medicines and Medical Devices Agency of Serbia.
Study: NCT05501132

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Patients will receive 10 sessions of 20 minutes of either 1 mA, 2 mA or sham electrical stimulation on 5 consecutive days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Patients will receive 10 sessions of 20 minutes of either 1 mA, 2 mA or sham electrical stimulation on 5 consecutive days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Patients will receive 10 sessions of 20 minutes of either 1 mA, 2 mA or sham electrical stimulation on 5 consecutive days
Study: NCT02466126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bCBT
Description: The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health).
Study: NCT01668485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoglycemic and euglycemic glucose clamp
Description: Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemic and euglycemic glucose clamp
Description: Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hypoglycemic and euglycemic glucose clamp
Description: Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
Study: NCT03368027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A cognitive-behavioral intervention program
Description: In this program, participants receive a training of assertive skills, social skills, acceptance, among other psychological aspects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention
Description: Participants receive different activities conducted by a psychologist in the association where the attend.
Study: NCT00421408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplement
Description: 40-g whey protein supplement daily for 18 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement daily for 18 months
Study: NCT00311831

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard gastroenteritis education
Description: Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
Study: NCT02783105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musical intervention
Study: NCT00311831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extensive gastroenteritis education
Description: Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
Study: NCT06549920

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal mammary node irradiation
Description: Irradiation of the internal mammary nodes in intercostal space 1-4.
Study: NCT01724814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
Study: NCT02783105

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
Study: NCT03850444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed